



# **Rising PSA Post LDR Brachytherapy – Recurrence or Bounce**

Dr Darren Mitchell  
Consultant Clinical Oncologist  
Northern Ireland Cancer Centre




Belfast Health and  
Social Care Trust






- A PSA bounce is defined as a rise of  $\geq 0.2\text{ng/ml}$  above an initial nadir with subsequent decline to or below that initial nadir without treatment.



- Different levels have been used
  - 0.1ng/ml
  - 0.2ng/ml
  - 0.4ng/ml
  - >35% above the preceding nadir





# Aetiology?




- Bacterial or radiation prostatitis
- Late radiation effect
- Persisting radiation proctitis
- Recent ejaculation
- Recent instrumentation
- Micro-vascular fibrosis/infarction



















# Christie experience




- 205 men
- Median FU 45months (24-85)
- 79 (37%) Bounce
- Median time to bounce 14.8months (1.7-40.6)
- Median Peak PSA 1.8ng/ml (0.4-7.4)
- Median Magnitude 0.91ng/ml (0.2-5.8)
- Median Duration 11.3months (2.3-32.5)


# Christie experience




- Younger Men (mean 60yrs vs 64yrs)
- ASTRO failure 5% vs 15% ( $p=0.02$ ) Mean 20.8months
- Phoenix failure 7.5% vs 15% ( $p=0.004$ ) Mean 28months
- False calls with both definition
  - 7 ASTRO
  - 8 Phoenix




## ASTRO





## Phoenix





- Velocity
  - $>1\text{ ng/ml}$
  - Considerable overlap







- Velocity
- No significant difference in PSAdt during bounce compared to ASTRO or Phoenix failures


	Christie (205)	Crook et al (292)	Stock et al (373)	Ceizki et al (162)	Pickles et al (468)	Patel et al (295)
% Bounce	37	40	17-31	46.3	71.4*	28
Median time to bounce (mo)	14.8	15.2	19.5-20.5	15.1	13	19.4 (no ADT)
Median Peak PSA (ng/ml)	1.8				1.1	
Magnitude (ng/ml)	0.91	0.76				0.6 (no ADT)
Duration (mo)	11.3	6.8			6.5	
Younger	✓	✓	✓	✓		✓
Time to Failure (A/P)	20.8 / 28	30.9		22.3 / 30		
Better Outcome	✓			✓		✓








# What is the best definition of failure following brachytherapy?



- British Columbia Cancer Agency
  - Nadir +2      2.4% False call
    - Christie      10%
    - PMH      15%
    - WBH      6%
  - Nadir +3      1.3% False call




# What is the best definition of failure following brachytherapy?



- William Beaumont Hospital
  - Nadir +5 for 2years
  - then nadir +2 particularly if <60yrs old
- WBH                      1.2%   False call
- PMH                      3.5%
- Christie                  2.5%

# Practical guidance



- PMH
  - Inform and reassure
  - Review pre-treatment and implant characteristics
  - Centralised review 3monthly
  - If PSA has not corrected by 30months then biopsy should be performed.
  - If PSA  $>10\text{ng/ml}$  then systemic investigations are warranted.

# Conclusion

- Current definitions of biochemical failure used following LDR prostate brachytherapy are prone to false calls as a consequence of the Benign PSA bounce phenomenon
- Commit to appropriate PSA surveillance
- Avoid the premature and inappropriate initiation of salvage therapy